Overview

A Study of Apatinib Treatment in for Advanced Ovarian Cancer

Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The study is evaluated the effacy and safety of apatinib combined with chemotherapy in the advanced ovarian cancer
Phase:
Phase 2
Details
Lead Sponsor:
The People's Hospital of Leshan
Collaborator:
Jiangsu HengRui Medicine Co., Ltd.
Treatments:
Apatinib